Download Files:
DBCO-(PEG2-VC-PAB-MMAE)2
SKU
HY-126690-1 mg
Category ADC Related
Tags Antibody-drug Conjugate/ADC Related, Cancer, Drug-Linker Conjugates for ADC
$280 – $1,300
Products Details
Product Description
– DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate[1]. DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
Web ID
– HY-126690
Storage Temperature
– -20°C, 3 years (Powder)
Shipping
– Blue Ice
Applications
– Cancer-programmed cell death
Molecular Formula
– C149H224N22O32
References
– [1]Brian Lannutti, et al. Ror1 antibody immunoconjugates. WO2018237335A1.
CAS Number
– 2259318-55-1
Molecular Weight
– 2835.50
Compound Purity
– 98.73
SMILES
– O=C(N1[C@](CCC1)([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C2=CC=CC=C2)O)=O)C[C@@H](OC)[C@@]([C@@H](C)CC)([H])N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC(C=C3)=CC=C3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCOCCOCCN(CCOCCOCCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC4=CC=C(COC(N(C)[C@@H](C(C)C)C(N[C@@H](C(C)C)C(N(C)[C@]([C@@H](C)CC)([H])[C@H](OC)CC(N5[C@](CCC5)([H])[C@H](OC)[C@@H](C)C(N[C@H](C)[C@H](C6=CC=CC=C6)O)=O)=O)=O)=O)=O)C=C4)=O)=O)=O)C(CCC(N7C8=CC=CC=C8C#CC9=CC=CC=C9C7)=O)=O)=O)=O)=O)=O)=O)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Drug-Linker Conjugates for ADC
Isoform
– Auristatin
Pathway
– Antibody-drug Conjugate/ADC Related
Product type
– ADC Related
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.